| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/100-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | APS2; DIPP3a; DIPP3-alpha |
| Entrez GeneID | 170685; |
| WB Predicted band size | 19kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Full length fusion protein of human NUDT10 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于NUDT1抗体的3篇参考文献及其摘要内容：
1. **"NUDT1 is critical for genomic stability and is a therapeutic target in cancer"**
- **作者**: Gad H, et al.
- **摘要**: 研究揭示了NUDT1(MTH1)在清除氧化损伤核苷酸中的关键作用，并开发了特异性抗体用于检测其在癌细胞中的表达。实验表明抑制NUDT1可导致DNA损伤和癌细胞死亡，抗体被用于验证基因沉默效果及蛋白水平变化。
2. **"Selective targeting of cancer cells by small molecule inhibitors of human NUDT1"**
- **作者**: Huber KV, et al.
- **摘要**: 该文献报道了一种高选择性NUDT1小分子抑制剂，并利用兔源多克隆抗体进行免疫印迹和免疫荧光实验，验证抑制剂对NUDT1蛋白表达的调控作用，证明其在实体瘤治疗中的潜力。
3. **"NUDT1 expression in tumor-associated macrophages promotes cancer progression and drug resistance"**
- **作者**: Yoshihara M, et al.
- **摘要**: 通过构建NUDT1特异性单克隆抗体，研究发现肿瘤微环境中巨噬细胞的NUDT1高表达与化疗耐药性相关，抗体被用于临床样本的免疫组化分析，揭示其作为预后标志物的可能性。
4. **"Antibody-based profiling of NUDT1 in human tissues reveals therapeutic vulnerabilities"**
- **作者**: Wang Z, et al.
- **摘要**: 研究开发了一种人源化NUDT1单克隆抗体，用于流式细胞术和免疫沉淀，系统分析了不同癌症类型中NUDT1的表达模式，发现其与肿瘤侵袭性正相关，为抗体偶联药物(ADC)开发提供依据。
(注：以上文献信息为模拟示例，实际引用时需核实原文准确性。)
The NUDT1 antibody is a crucial tool for studying the NUDT1 protein, also known as MTH1 (MutT homolog 1), a nucleotide phosphatase involved in maintaining genomic integrity. NUDT1 hydrolyzes oxidized purine nucleoside triphosphates (e.g., 8-oxo-dGTP), preventing their incorporation into DNA during replication and thereby reducing oxidative DNA damage. This enzyme is particularly significant in cancer biology, as many tumors exhibit elevated NUDT1 expression due to high oxidative stress, which supports cancer cell survival and contributes to chemoresistance. Inhibitors targeting NUDT1 have emerged as potential anticancer agents, driving interest in detecting and quantifying its expression in research and therapeutic contexts.
NUDT1 antibodies are widely used in techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to evaluate protein expression levels across tissues or cell lines. They help elucidate NUDT1's role in cancer progression, DNA repair mechanisms, and response to therapies, including platinum-based drugs. Validated antibodies are essential for specificity, as cross-reactivity with homologous proteins (e.g., NUDT15) can compromise data accuracy. Recent studies also explore NUDT1's potential as a biomarker for patient stratification or therapeutic targeting. However, discrepancies in antibody performance across commercial sources or experimental conditions highlight the need for rigorous validation, such as using knockout controls or orthogonal methods. Overall, NUDT1 antibodies remain pivotal in advancing our understanding of oxidative stress management in cancer and beyond.
×
